Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
This opportunity solicits Direct-to-Phase II proposals to advance small-molecule candidates that are ready for Phase II testing, focusing on broad-spectrum, fungicidal activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary goal is to identify a safe antifungal small molecule suitable for patient use and capable of achieving FDA clearance.
Source
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Minor Use Minor Species Development of Drugs (R01)
Food and Drug Administration
-
NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
National Institutes of Health
-
Minor Use Minor Species Development of Drugs (R01)
Food and Drug Administration
-
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
-
NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
National Institutes of Health
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers